References
- Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1996; 29A: 2077–92.
- The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903.
- Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinothecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–60.
- Lavrenkov K, Man S, Mermershtain W, Cohen Y. Retrospective comparison of single agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer. J Chemother 2002; 14: 84–7.
- Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluouracil compared with fluouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041–7.
- Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus flu-ouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 543: 905–12.
- Sargent D, Niedzwiecki D, O'Connell M, et al. Recommendation for caution with irinothecan, fluouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 144–5.
- Rothenberg M, Meropol, Poplin E, et al. Mortality asso-ciated with irinothecan plus bolus fluouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001; 19: 3801–7.
- Elfring G, Emanuel D, Rostagi R, et al. Patterns of use and mortality in the community oncology practice setting among patients receiving first-line weekly bolus irinothecan/5-fluouracil/leucovorin (IFL) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21: 133a, (abstr 530).
- Van Cutsem E, Douillard JY, Kohne C. Toxicity of irinothecan in patients with colorectal cancer. N Engl J Med 2001; 345: 1351–2.